What Is Amenorrhea? Causes, Symptoms, Types, and Treatment

Defining Amenorrhea: What It Means Clinically

Amenorrhea is not a diagnosis in itself. It is a clinical sign, the absence of menstrual bleeding, that points toward a wide range of underlying conditions. Physicians classify it into two types based on whether periods have ever occurred, because the two categories carry different differential diagnoses and require different initial workups.

The American College of Obstetricians and Gynecologists (ACOG) defines primary amenorrhea as the absence of menarche by age 15 in a person with otherwise normal pubertal development, or by age 13 if no secondary sex characteristics (breast budding, pubic hair) have appeared. Secondary amenorrhea is defined as the absence of menstruation for three or more consecutive months in someone who previously had regular cycles, or six months in someone with irregular cycles. [1]

A normal menstrual cycle runs 21 to 35 days. Missing a single period is common and usually self-limiting, but three consecutive missed periods warrant a clinical evaluation.

Primary Amenorrhea: Causes and Evaluation

Primary amenorrhea signals that something interrupted the developmental axis before the first period ever began. The causes divide cleanly into chromosomal, anatomical, and hormonal categories.

Chromosomal and Genetic Causes

Turner syndrome (45,X karyotype) is the single most common chromosomal cause of primary amenorrhea, accounting for roughly 30% of cases referred to specialist centers. [2] Affected individuals typically have streak gonads, short stature, and elevated FSH and LH because the hypothalamic-pituitary axis is functioning but the ovaries cannot respond.

Complete androgen insensitivity syndrome (CAIS) presents a different picture. Individuals have a 46,XY karyotype but appear phenotypically female due to end-organ insensitivity to androgens. Testosterone levels are in the male reference range, but virilization never occurs.

Anatomical Causes

Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome, MRKH) accounts for 10-15% of primary amenorrhea cases. The uterus is absent or rudimentary, the ovaries are normal, and estrogen levels are normal, so breast development and bone density are preserved. [3]

An imperforate hymen or transverse vaginal septum can also block menstrual outflow without any hormonal abnormality. Cyclic pelvic pain in the absence of visible bleeding is the hallmark symptom that prompts pelvic imaging.

Hormonal Causes Beginning Before Menarche

Hypothalamic or pituitary dysfunction that begins in childhood or adolescence can delay or prevent the first period. Kallmann syndrome combines absent GnRH secretion with anosmia. Pituitary adenomas (prolactinomas) raise prolactin and suppress GnRH pulsatility.

Secondary Amenorrhea: The Most Common Causes

Secondary amenorrhea is far more prevalent than primary amenorrhea in clinical practice. A 2021 review in the Journal of Clinical Endocrinology and Metabolism estimated that secondary amenorrhea affects 3-5% of the general female population at any given time, rising to 40-60% among elite endurance athletes. [4]

Hypothalamic Amenorrhea

Hypothalamic amenorrhea (HA) is the leading non-pregnancy cause of secondary amenorrhea. It arises when the hypothalamus reduces GnRH pulse frequency in response to one or more of three triggers: caloric deficit (low energy availability), psychological stress, or excessive exercise. The result is low FSH, low LH, low estradiol, and anovulation, with the entire hypothalamic-pituitary-ovarian axis functionally suppressed.

A 2020 Endocrine Society Clinical Practice Guideline states: "We suggest that clinicians diagnose functional hypothalamic amenorrhea in women with secondary amenorrhea, low or normal gonadotropins, and low estrogen after excluding organic hypothalamic or pituitary disease." [5]

Bone loss is the most serious long-term consequence. Studies using dual-energy X-ray absorptiometry (DXA) show that lumbar spine bone mineral density in women with HA is, on average, 13-20% lower than in age-matched controls with normal cycles. [6]

Polycystic Ovary Syndrome (PCOS)

PCOS is the most common endocrine disorder in reproductive-age women, affecting 6-12% by the Rotterdam criteria. [7] Amenorrhea or oligomenorrhea (fewer than 8 cycles per year) is present in up to 70% of PCOS cases. The pathophysiology involves elevated LH pulse amplitude, elevated androgens, and insulin resistance impairing normal follicle selection.

Unlike hypothalamic amenorrhea, estrogen levels in PCOS are usually normal or elevated (chronic anovulation leads to unopposed estrogen from peripheral aromatization of androgens). This distinction matters clinically: women with PCOS have near-normal bone density but an elevated endometrial cancer risk from unopposed estrogen.

Thyroid Dysfunction and Hyperprolactinemia

Both hypothyroidism and hyperthyroidism can disrupt menstrual regularity, and both are correctable once identified. Hypothyroidism elevates TRH, which in turn stimulates prolactin secretion. Elevated prolactin directly inhibits GnRH pulsatility.

A prolactin-secreting pituitary adenoma (prolactinoma) is present in approximately 30% of women presenting with secondary amenorrhea plus galactorrhea (spontaneous breast milk production). [8] MRI of the pituitary is indicated when serum prolactin is persistently above 100 ng/mL.

Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI), previously called premature menopause, is defined as ovarian failure before age 40. It affects approximately 1% of women under 40 and 0.1% under 30. [9] The laboratory pattern mirrors menopause: elevated FSH (typically above 25 IU/L on two measurements taken 4 weeks apart), elevated LH, and low estradiol. Causes include autoimmune destruction, FMR1 (fragile X) premutation, Turner mosaic karyotype, and prior chemotherapy or pelvic radiation.

POI is not amenable to reversal in most cases. Hormone replacement therapy is the standard of care to protect bone, cardiovascular health, and cognitive function until the natural age of menopause.

Less Common but Clinically Important Causes

Asherman Syndrome

Asherman syndrome describes intrauterine adhesions (scarring) that obliterate the endometrial cavity, preventing normal shedding. The most common antecedent is uterine instrumentation, particularly dilation and curettage (D&C) after pregnancy loss or termination. In a cohort study published in Fertility and Sterility, Asherman syndrome was identified in 13-39% of women who underwent repeat D&C for retained products of conception. [10]

Diagnosis is confirmed by hysteroscopy or saline infusion sonography. Treatment is hysteroscopic adhesiolysis.

Medications and Exogenous Hormones

Several drug classes suppress menstruation through different mechanisms.

• Depot medroxyprogesterone acetate (Depo-Provera, 150 mg IM every 12 weeks): amenorrhea occurs in 50% of users after 1 year and 80% after 5 years of continuous use. [11]
• Continuous combined oral contraceptive regimens prescribed for endometriosis or cycle suppression.
• Antipsychotics (risperidone, haloperidol) that raise prolactin via dopamine D2 receptor blockade.
• GnRH agonists (leuprolide acetate, Lupron) used for endometriosis or uterine fibroids.

Medication-induced amenorrhea is generally reversible after discontinuation, though the timeline varies.

Celiac Disease and Malabsorptive States

Undiagnosed celiac disease is an under-recognized cause of hypothalamic amenorrhea. Nutrient malabsorption (zinc, selenium, iron) and systemic inflammation both suppress GnRH pulsatility. A 2019 meta-analysis found that women with celiac disease had a 3.5-fold higher odds of reporting menstrual irregularity compared with controls (OR 3.5, 95% CI 2.0-6.1). [12]

Symptoms Beyond Missed Periods

Amenorrhea itself is the primary symptom, but the underlying cause produces additional findings that guide diagnosis.

Symptoms by Cause

| Cause | Associated Symptoms | |---|---| | Hypothalamic amenorrhea | Fatigue, cold intolerance, low libido, stress fractures | | PCOS | Hirsutism, acne, central adiposity, acanthosis nigricans | | Hyperprolactinemia | Galactorrhea, headache, visual field changes | | POI | Hot flashes, night sweats, vaginal dryness, mood changes | | Turner syndrome | Short stature, webbed neck, bicuspid aortic valve | | Asherman syndrome | Cyclic pelvic pain with absent bleeding |

Hot flashes and vaginal dryness in a woman under 40 should trigger immediate FSH and LH measurement to rule out POI. Galactorrhea in a non-postpartum woman warrants urgent prolactin testing.

Diagnostic Workup: Step-by-Step

A structured approach prevents missed diagnoses and unnecessary testing. Pregnancy must be excluded first, regardless of the clinical story.

Step 1: Rule Out Pregnancy

Serum beta-hCG is more sensitive than urine testing (detects levels as low as 5 mIU/mL vs. 20-25 mIU/mL for most urine strips). Order it in every reproductive-age patient before proceeding.

Step 2: Initial Hormone Panel

After confirming a negative pregnancy test, the standard first-line panel includes:

• FSH and LH (to distinguish hypothalamic/pituitary causes from ovarian failure)
• Estradiol (E2)
• Prolactin (two measurements if elevated, given pulsatile secretion)
• TSH (thyroid disease is common and treatable)
• Free and total testosterone plus DHEA-S if PCOS or androgen excess is suspected

Step 3: Imaging

Pelvic ultrasound evaluates uterine and ovarian morphology. Polycystic ovarian morphology (12 or more follicles measuring 2-9 mm per ovary on transvaginal ultrasound, or ovarian volume above 10 mL) supports a PCOS diagnosis. [7]

MRI of the pituitary sella is ordered when prolactin is persistently elevated or when visual field defects suggest a mass lesion.

Step 4: Specialized Testing

• Karyotype: indicated in primary amenorrhea with elevated FSH (to identify Turner syndrome or CAIS).
• AMH (anti-Müllerian hormone): a marker of ovarian reserve; very low levels support POI.
• DXA scan: bone mineral density assessment is recommended in any woman with amenorrhea lasting more than 6 months. [5]
• Hysteroscopy or saline infusion sonography: when Asherman syndrome is suspected.

The HealthRX clinical team uses the following triage framework for new amenorrhea presentations: (1) beta-hCG same day, (2) FSH, LH, prolactin, TSH, estradiol within 1 week, (3) pelvic ultrasound within 2 weeks, (4) pituitary MRI only when prolactin exceeds 100 ng/mL or visual symptoms are present, (5) DXA at 6 months if etiology is not reversed. This sequence avoids premature advanced imaging while catching the most actionable diagnoses quickly.

Treatment Options by Cause

Treatment is never one-size-fits-all. The goal is to address the root cause, restore ovulatory cycles when fertility is desired, and protect long-term health (especially bone and cardiovascular).

Treating Hypothalamic Amenorrhea

The primary intervention is increasing energy availability. A 2019 randomized controlled trial (N=60) published in the Journal of Clinical Endocrinology and Metabolism found that cognitive behavioral therapy (CBT) targeting eating behaviors and exercise patterns restored ovulatory cycles in 88% of participants over 20 weeks, compared with 25% in a control observation group (P<0.001). [13]

Nutritional rehabilitation targets energy availability above 45 kcal per kg of fat-free mass per day, the threshold identified by the 2014 Female Athlete Triad Coalition Consensus Statement. [14] Weight restoration alone restores periods in the majority of women with low BMI-driven HA.

Medications are second-line. Pulsatile GnRH therapy (via pump) can restore ovulation when behavioral measures fail, particularly in women seeking fertility. Letrozole and clomiphene citrate are used for ovulation induction. Estrogen-progestin oral contraceptives treat symptoms but do not address the underlying energy deficit and may mask ongoing bone loss.

Treating PCOS-Related Amenorrhea

Lifestyle modification remains first-line for overweight women with PCOS. A 5-10% reduction in body weight can restore spontaneous ovulation in up to 80% of affected women. [15]

Cyclic or continuous progestin (medroxyprogesterone acetate 10 mg for 10-14 days every 1-3 months) induces a withdrawal bleed, protecting the endometrium from hyperplasia. Combined oral contraceptives achieve the same endometrial protection while also managing hirsutism.

Metformin (500-2000 mg/day, titrated to tolerance) improves insulin sensitivity and can restore ovulatory cycles in insulin-resistant PCOS patients. The American Diabetes Association includes metformin as a standard option in PCOS metabolic management. [16]

For fertility, clomiphene citrate 50-150 mg on cycle days 3-7 achieves ovulation in 60-85% of PCOS patients and conception in 30-40% per cycle. Letrozole 2.5-7.5 mg achieves higher live birth rates than clomiphene in PCOS, as demonstrated in the PPCOS II trial (N=750), which reported a live birth rate of 27.5% with letrozole vs. 19.1% with clomiphene (P=0.007). [17]

Treating Hyperprolactinemia

Dopamine agonists are the medical treatment of choice. Cabergoline 0.25-1.0 mg twice weekly normalizes prolactin in over 85% of patients and reduces tumor size in most microadenomas. Bromocriptine 1.25-2.5 mg twice daily is an older alternative with a less favorable side-effect profile but established safety data in pregnancy. [8]

Menstrual cycles typically resume within 3-6 months of achieving normal prolactin levels.

Treating Premature Ovarian Insufficiency

Hormone replacement therapy (HRT) is the standard of care for POI. ACOG and the Menopause Society (formerly NAMS) recommend HRT until the natural age of menopause (approximately age 51-52) to protect bone density, cardiovascular health, and quality of life. [9]

Typical regimens use estradiol 1-2 mg orally or 0.05-0.1 mg transdermally plus cyclic micronized progesterone 200 mg for 12 days per month in women with an intact uterus. Spontaneous pregnancy does occur in POI (estimated 5-10% of cases over a lifetime), so contraception is still required in women who do not desire pregnancy.

Treating Anatomical Causes

Hysteroscopic adhesiolysis for Asherman syndrome restores menstrual bleeding in 70-85% of cases, though pregnancy outcomes depend heavily on the severity of adhesions. [10]

Müllerian agenesis (MRKH) requires vaginal dilation therapy or surgical vaginoplasty to enable sexual intercourse. Fertility is possible through gestational surrogacy using the patient's own eggs.

Long-Term Health Risks of Untreated Amenorrhea

Prolonged amenorrhea carries risks beyond infertility. Bone mineral density loss is the most immediate concern. For every year of amenorrhea, cortical bone loss averages 1-3% and may not be fully reversible even after menstrual recovery. [6]

Women with PCOS and chronic anovulation face a 3-fold elevated risk of endometrial hyperplasia and a measurably higher endometrial cancer incidence over their lifetime without progestin protection. [7]

Cardiovascular risk also rises with prolonged hypoestrogenic states (hypothalamic amenorrhea, POI), given estrogen's role in vascular endothelial function and lipid metabolism. The American Heart Association recognizes premature menopause and POI as independent cardiovascular risk factors. [18]